Haihong Pu

926 total citations
16 papers, 661 citations indexed

About

Haihong Pu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Haihong Pu has authored 16 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Haihong Pu's work include Cancer Immunotherapy and Biomarkers (8 papers), Ferroptosis and cancer prognosis (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Haihong Pu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Ferroptosis and cancer prognosis (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Haihong Pu collaborates with scholars based in China. Haihong Pu's co-authors include Shu Zhao, Minghui Zhang, Hongli Zhao, Minghui Zhang, Qingyuan Zhang, Yan Wang, Guoliang Li, Yan Wang, Yanbo Wang and Kaibin Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Haihong Pu

16 papers receiving 658 citations

Peers

Haihong Pu

ONCOL

PRM

IMMUN

Peijian Peng China

Jiani C. Yin China

Adam R. Wolfe United States

Nuria Kotecki Belgium

Ayush Arya United States

Meredith A. Tennis United States

Daniela Morales-Espinosa Spain

Francesca Simionato Italy

Luis Paz Ares Spain

He-Li Gao China

Peijian Peng China

Haihong Pu

558 ×1.3

ONCOL

385 ×1.4

PRM

183 ×1.0

152 ×0.8

142 ×1.1

IMMUN

Citations per year, relative to Haihong Pu Haihong Pu (= 1×) peers Peijian Peng

Countries citing papers authored by Haihong Pu

Since Specialization

Citations

This map shows the geographic impact of Haihong Pu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haihong Pu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haihong Pu more than expected).

Fields of papers citing papers by Haihong Pu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haihong Pu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haihong Pu. The network helps show where Haihong Pu may publish in the future.

Co-authorship network of co-authors of Haihong Pu

This figure shows the co-authorship network connecting the top 25 collaborators of Haihong Pu. A scholar is included among the top collaborators of Haihong Pu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haihong Pu. Haihong Pu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Li, Lijun, et al.. (2025). Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021. BMC Public Health. 25(1). 911–911. 3 indexed citations

Li, Lijun, et al.. (2025). Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology. 209. 104683–104683. 3 indexed citations

Zhao, Yanbin, et al.. (2024). Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.. Journal of Clinical Oncology. 42(16_suppl). e20107–e20107. 1 indexed citations

Liu, Jinglei, et al.. (2023). Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338–3p/RAB1B axis. Pathology - Research and Practice. 245. 154435–154435. 5 indexed citations

Zhang, Minghui, et al.. (2022). CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma. Frontiers in Immunology. 13. 806877–806877. 24 indexed citations

Zhao, Yanbin, et al.. (2021). Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment. Frontiers in Oncology. 10. 585961–585961. 29 indexed citations

Xu, Chunlin, et al.. (2021). MiR-342-3p inhibits LCSC oncogenicity and cell stemness through HDAC7/PTEN axis. Inflammation Research. 71(1). 107–117. 9 indexed citations

Zhang, Minghui, Kaibin Zhu, Haihong Pu, et al.. (2019). An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma. Frontiers in Oncology. 9. 1314–1314. 113 indexed citations

Ma, Jianli, Yan Wang, Yubo Yan, et al.. (2018). Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. Journal of Cancer. 9(19). 3489–3499. 9 indexed citations

10.

Shi, Lei, Chunbo Zhao, Haihong Pu, & Qingyuan Zhang. (2017). FBP1 expression is associated with basal-like breast carcinoma. Oncology Letters. 13(5). 3046–3056. 13 indexed citations

11.

Zhang, Minghui, Guoliang Li, Yanbo Wang, et al.. (2017). PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Scientific Reports. 7(1). 10255–10255. 172 indexed citations

12.

Pu, Haihong, Qingyuan Zhang, Chunbo Zhao, et al.. (2017). VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer. Pathology & Oncology Research. 24(3). 557–565. 5 indexed citations

13.

Zhang, Minghui, et al.. (2017). Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget. 8(31). 51630–51640. 52 indexed citations

14.

Zhang, Minghui, et al.. (2017). Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget. 8(19). 31347–31354. 157 indexed citations

15.

Zhao, Chunbo, Lei Shi, Haihong Pu, & Qingyuan Zhang. (2016). The Promoting Effect of Radiation on Glucose Metabolism in Breast Cancer Cells under the Treatment of Cobalt Chloride. Pathology & Oncology Research. 23(1). 47–53. 11 indexed citations

16.

Pu, Haihong, Qingyuan Zhang, Chunbo Zhao, et al.. (2015). Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma. World Journal of Surgical Oncology. 13(1). 323–323. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact